Bovine IgG ELISA Kit

Purpose of review Intravenous immunoglobulin (IVIg) is an effective treatment for an increasing number of autoimmune and inflammatory conditions. However, IVIg continues to be limited by problems of potential shortages and cost. A number of mechanisms have been described for IVIg, which have been captured in newly emergent IVIg mimetic and IVIg alternative therapies. This review discusses the recent developments in IVIg mimetics and alternatives. Recent findings Newly emergent IVIg mimetics and alternatives capture major proposed mechanisms of IVIg, including Fc gamma R blockade, FcRn inhibition, complement inhibition, immune complex mimetics and sialylated IgG. Many of these emergent therapies have promising preclinical and clinical trial results. Significant research has been undertaken into the mechanism of IVIg in the treatment of autoimmune and inflammatory disease. Understanding the major IVIg mechanisms has allowed for rational development of IVIg mimetics and alternatives for several IVIg-treatable diseases.

Dengue virus (DENV) is one of the most serious arthropod-borne viruses. This study was performed to investigate the prevalence of the virus in Najran, a city in the south west of Saudi Arabia. Four hundred and ten paired maternal and umbilical serum samples were obtained from mothers and their newborn infants. The samples were tested for the presence of IgG antibodies by ELISA. Anti-DENV IgG antibodies were detected in 31 maternal samples (7.6%), while all newborn samples were negative. All maternal seropositive samples were negative when tested by PCR. These results are further indication that DENV is endemic in Saudi Arabia and enhanced DENV surveillance is necessary.